Low molecular weight heparin: a practical approach in deep venous thrombosis in palliative care.

INTRODUCTION

Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin.

AIMS

Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical utility in palliative care settings.

MATERIALS AND METHODS

Twelve cases of established DVT received enoxaparin at 40 mg/m with warfarin.

RESULTS

There was 70% resolution of limb swelling in seven cases. Out of remaining four cases took two months to resolve and one case did not resolve completely.

CONCLUSIONS

LMV heparin is effective in palliative care setting and also has added advantage of subcutaneous route of administration.